[TruScreen Combined With High-Risk Human Papillomavirus Testing vs Thinprep Cytology Test Combined With High-Risk...

To compare the clinical value of TruScreen, an artificial intelligence-based real-time cervical cancer screening system, combined with high-risk human papillomavirus (hr-HPV) test and Thinprep cytology test (TCT) combined with hr-HPV test in cervical cancer screening.

A total of 297 women undergoing cervical cancer screening at Panzhihua Central Hospital between June 2020 and December 2023 were enrolled. All participants underwent hr-HPV testing, TCT, and TruScreen test. The diagnostic performance of TruScreen combined with hr-HPV test and TCT combined with hr-HPV test for low-grade squamous intraepithelial lesion positive (LSIL⁺) and high-grade squamous intraepithelial lesion positive (HSIL⁺) cervical lesions was evaluated.

Among the 297 enrolled women, pathology analysis identified 128 (43.10%) LSI⁺ cases and 67 (22.56%) HSIL⁺ cases. Additionally, there were 110 (37.04%) HPV16/18 positive cases, 177 (59.60%) cases with TCT results ≥ atypical squamous cells of undetermined significance (ASCUS), and 176 (59.26%) cases with abnormal TruScreen results. The area under the curve (AUC) of TruScreen combined with hr-HPV test in diagnosing LSIL⁺ and HSIL⁺ cervical lesions was higher than that of TCT combined with hr-HPV test (P < 0.05).

TruScreen combined with hr-HPV test demonstrates superior performance in cervical cancer screening compared with TCT combined with hr-HPV test. TruScreen combined with hr-HPV test may serve as an alternative to conventional cytology-based methods for cervical cancer screening in China.